Literature DB >> 1981577

The parenteral controlled release of liposome encapsulated chloroquine in mice.

H A Titulaer1, W M Eling, D J Crommelin, P A Peeters, J Zuidema.   

Abstract

Free (0.6 mg), and liposome encapsulated chloroquine (0.6, 3 mg), were injected intraperitoneally, intramuscularly and subcutaneously in mice. Intraperitoneal administration of liposome-encapsulated chloroquine resulted in high and long lasting concentrations of chloroquine in the blood compared with intraperitoneal administration of free chloroquine. After administration of the liposome-encapsulated chloroquine the concentrations in the spleen were also higher, indicating that chloroquine liposomes reached the blood compartment intact after intraperitoneal administration. After intramuscular and subcutaneous administration the chloroquine liposomes acted as a local depot, giving a slower release from the subcutaneous fat layer than from the muscle depot. After the 0.6 mg dose a burst effect was found at about 7 h in most of the animals; this was not found after the 3 mg dose. This finding and the slower release after the 3 mg dose than after the 0.6 mg dose could be explained by the formation of aggregates after the injection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981577     DOI: 10.1111/j.2042-7158.1990.tb07052.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  In vitro-in vivo myotoxicity of intramuscular liposomal formulations.

Authors:  S A al-Suwayeh; I R Tebbett; D Wielbo; G A Brazeau
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

2.  Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.

Authors:  Thais Alves da Costa-Silva; Andrés Jimenez Galisteo; José Angelo Lauletta Lindoso; Leandro R S Barbosa; Andre Gustavo Tempone
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 3.  Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine.

Authors:  David M Stevens; Rachael M Crist; Stephan T Stern
Journal:  Molecules       Date:  2020-12-31       Impact factor: 4.411

4.  A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.

Authors:  Peter B Madrid; Sidharth Chopra; Ian D Manger; Lynne Gilfillan; Tiffany R Keepers; Amy C Shurtleff; Carol E Green; Lalitha V Iyer; Holli Hutcheson Dilks; Robert A Davey; Andrey A Kolokoltsov; Ricardo Carrion; Jean L Patterson; Sina Bavari; Rekha G Panchal; Travis K Warren; Jay B Wells; Walter H Moos; Raelyn L Burke; Mary J Tanga
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.